Cardiology

The mapping system incorporate referencing based on 3D navigation, similar to what is used for brain, spine, ENT, and lung surgeries.

The latest scientific statement from the American Heart Association seeks to outline the cardiovascular risks associated with OSA or sleep-disordered breathing in children and adolescents while also providing insight into symptoms and risk factors for developing OSA or sleep-disordered breathing.

Dr. Saxe discusses the role of nutrition in determining levels of inflammation and its potential in treating patients.

The main mechanism for exercise intolerance is impaired blood oxygen carrying capacity.

The study notes the importance of follow-up monitoring of sleep apnea in patients with IH.

There was little difference in hospitalization and mortality rates between vaccinated schizophrenia patients and vaccinated control patients.

An analysis of data from a prospective cohort study of more than 50k suggests increased intake of vitamin K could lower a person's risk of ASCVD hospitalization by more than 20%.

The technology will be implemented into Acutus Medical’s AcQMap 3D imaging and mapping systems.

Investigators believe benefit of COVID-19 vaccination outweigh the risk of myocarditis in adolescent population.

In an analysis, low GI/GL dietary patterns resulted in a reduction in HbA1c, compared with control diets with a mean difference of −0.31.

Dr. Gregory Weiss reflects on the history of artificial intelligence in cardiology and offers perspective on its evolving role as artificial intelligence has demonstrated its ability to improve care and clinical decision-making.

Our latest case report from Brady Pregerson, MD, features a man in his 40s presenting to the ED for a first time seizure and denying near-syncope, palpitations, chest pain, and other complaints. Can you determine the correct diagnosis?

Patients with metabolic syndrome were at a 46% increased risk of a second stroke and a 27% increased risk of mortality when compared to their counterparts without metabolic syndrome.

Data show the change in 24-hour ambulatory systolic blood pressure was significant between treatment and control groups with a reduction of 7.1 mm Hg.

Experts discuss key takeaways from the review article “Role of Bempedoic Acid in Clinical Practice”, clinical implications, and the greatly anticipated CLEAR Outcomes trial.

Experts examine the safety and efficacy data presented within the review article, “Role of Bempedoic Acid in Clinical Practice.”

A new study suggests moderate caloric restriction combined with aerobic exercise could improve vascular health in older patients with obesity.

Kelly Chin, MD discusses the recent FDA approval of selexipag IV and breakthroughs in the cardiovascular care space.

An ancillary study to the INFINITE trial details the benefits of caloric restriction plus exercise versus exercise alone on aortic stiffness measured using CMRI in older adults with obesity.

The platform leverages optical coherence tomography and Ultreon Software.

With FDA clearance announced in a statement on August 3, the Ultreon Software, which combines OCT imaging with artificial intelligence, could help improve diagnosis and treatment compared to traditional imaging methods.

Data show the expression levels of miR-214, BNP, NT-proBNP, and sST2 were significantly higher compared to the control group.

Our latest case report from Brady Pregerson, MD, features a man in his mid-60s presenting to the ED after his primary care provider referred him for 6 hours of vomiting that had occurred the day prior. Can you determine the correct diagnosis?

Dr. Gregory Weiss, a cardiovascular anesthesiologist, offers perspective on the topic of long COVID syndrome and how the prospect of this phenomenon impacts clinical settings.

The FDA approved selexipag tablets for PAH in 2015.

Dr. Paul Thompson reflects on his experiences as a practicing cardiologist, including having the ability to impact early-career clinicians and what he gains when presented with the opportunity to teach other providers.

Data show a patient aged 65 years would have an extrapolated mean event-free survival of 6.2 years for placebo and 8.3 years for dapagliflozin, at a gain of 2.1 years.

In this series of HCPLive® State of the Science, 4 experts discuss knowledge and treatment in the cardiovascular risk management space.

Data show dapagliflozin was projected to add 0.63 quality-adjusted life-years at an incremental lifetime cost of $42, 800.